Hologic initiated with a Peer Perform at Wolfe amid near-term headwinds

As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Hologic (HOLX) with a Peer Perform rating and no price target The Diagnostics & Med Tech company caters to the healthcare and clinical end markets and the firm calls the company “an intriguing asset with a strong management team and unique portfolio.” However, while material downside risk is likely limited from here, the firm feels near term respiratory headwinds and saline shortages likely make expectations too high and calls it “best to stay on the sidelines for now.”